New drugs and clinical trials in diabetes and hypertension

Experimental and Clinical Endocrinology and Diabetes

Volumn 105, Issue SUPPL. 2, 1997, Pages 64-68

  Nilsson, Peter ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Clinical trials; Diabetes; Hypertension; Insulin resistance; Troglitazone

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEW DRUG; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0030846836     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211801     Document Type: Review

References (68)

1. Abrarira C, Colwell JA, Nuttall FQ, et al. Veterans affairs cooperative study on glycemic control and complications in type II diabetes (VA CSDM). Diab Care 18: 1113-23, 1995
2. Akanuma Y, Kosaka K, Kuzuya T, Shigeta Y, Kaneko T. Clinical evaluation of a new oral hypoglycemic agent CS-045 in NIDDM. Diabetologia 36 (suppl 1): abstract 700, 1993
3. Barker DJP (ed). Fetal and infant origins of adult disease. 1st edition. British Medical Journal. London, 1992
4. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36: 62-7, 1993
5. Beck-Nielsen H and the GR92132 Study group. Effects of GR92132X, a thiazolidinedione, in non-insulin-dependent diabetic patients. Diabetologia 37 (suppl. 1): A209:806, 1994
6. Björntorp P, de Jounge K, Sjöström L. The effect of physical training on insulin production in obesity. Metabolism 19: 631-8, 1970
7. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diab Care 15: 792-805, 1992
8. Cederholm J, Wibell L. Glucose intolerance in middle-aged males - a cause of hypertension? Acta Med Scand 217: 363-71, 1985
9. Dahlöf B, Hansson L, Lindholm LH, et al. STOP-Hypertension 2: A prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure 2: 136-41, 1993
10. DeFronzo R, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic disease. Diab Care; 14: 173-94, 1991
11. Dewailly D, Cortet-Rudelli C. Insulin resistance and the polycystic ovary syndrome. Horm Res 38: 41-5, 1992
12. Dorella M, Da Tos V, Campagnolo M, Giusto M, Ceoletto G, Palatini P, Semplicini A, Del Prato S, Metformin (MET) treatment in non-diabetic hypertensive patients. Diabetes 42 (suppl 1): abstract 181, 1993
13. Endre T, Mattiasson I, Hulthén UL, Lindgärde F, Berglund G. Insulin resistance is coupled to low physical fitness in normotensive men with a family history of hypertension. J Hypertens 12: 81-8, 1994
14. Facchini F, Hollenbeck C, Jeppesen J, Ida Chen Y-D, Reaven GM. Insulin resistance and cigarette smoking. Lancet 339: 1128-30, 1992
15. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: Impairment with increased blood pressure and body mass. Lancet 342: 707-9, 1993
16. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study, 1984-1991. Am J Epidemiol 140: 857-69, 1994
17. Ferrari P, Weidmann P, Shaw S, et al. Altered insulin sensitivity, hyperinsulinaemia and dyslipidaemia in individuals with a hypertensive parent. Am J Med 91: 589-96, 1991
18. Flier JS, Lilly Lecture: Syndromes of insulin resistance. Diabetes 41: 1207-19, 1992
19. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-58, 1988
20. Fujiwara T, Wada M, Fukuda K, et al. Characterization of CS-045, a new oral antidiabetic agent, II. Effect on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40; 1213-18, 1991
21. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormonal replacement therapy. Metabolism 42: 846-53, 1993
22. Haffner S, Mitchell B, Stern M, et al. Decreased prevalence of hypertension in Mexican-Americans. Hypertension 16: 225-32, 1990
23. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heissermann JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetologia 42: 1297-302, 1993
24. Hermann LS, Melander A: Biguanides: basic aspects and clinical uses. In. International Textbook of Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen HA, Zimmet PA, Eds, New York, Wiley, p. 773-95, 1992
25. Hermann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diab Care 15: 1075-78, 1992
26. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. The Hypertension in Diabetes Study Group. J Hypertens 11: 309-17, 1993
27. Iwamoto Y, Kuzuya T, Mtsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diab Care 14: 1083-86, 1991
28. Iwamoto Y, Shiraishi I, Kuzuya T, Kumakura S, Awata T, Saito T. Effect of CS-045 treatment on serum proinsulin level in NIDDM patients. Diabetes 42 (suppl 1): A180, 1993
29. Jarret J. In defence of insulin: a critique of Syndrome X. Lancet 340: 469-71, 1992
30. Julius S, Gudbrandsson T, Jamerson K, Shab ST, Andersson OK. The hemodynamic link between insulin resistance and hypertension. J Hypertens 9: 983-6, 1993
31. Kristiansson K, Sigfusson N, Sigvaldason H, Thorgeirsson G. Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study. J Hypertens 13: 581-6, 1995
32. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Internal Med 227: 273-78, 1990
33. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Internal Med 229: 181-7, 1991
34. Lind L, Andersson P-E, Andrén B, Hänni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 13: 433-8, 1995
35. Lithell HO. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diab Care 14: 203-9, 1991
36. Miura K, Nkagawa H, Nishijo M, et al. Plasma insulin and blood pressure in normotensive Japanese men with normal glucose tolerance. J Hypertens 13: 427-32, 1995
37. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose tolerance. J Clin Invest 75: 809-17, 1985
38. Morales PA, Mitchell BD, Valdez RA, Hazuda HP, Stern MP, Haffner SM. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio Heart Study. Diabetes 42: 154-61, 1993
39. Mårin P, Holmäng S, Sjöström L, et al. The effects of testosteron treatment on body composition and metabolism in middle-aged obese men. Int J Obes 16: 991-97, 1992
40. Nagi DK, Hendra TJ, Ryle AJ, Yudkin JS, et al. The relationships of concentration of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type II (non-insulin-dependent) diabetic subjects. Diabetologia 33: 532-37, 1990
41. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diab Care 16: 621-29, 1993
42. Nilsson P, Lindholm L, Scherstén B. Hyperinsulinemia and other metabolic disturbances in well-controlled hypertensive men and women: an epidemiological study of the Dalby population. J Hypertens 8: 953-9, 1990
43. Nilsson P, Lindholm L, Scherstén B. Life style changes improve insulin resistance in hyperinsulinemic subjects: a one-year intervention study of hypertensives and normotensives in Dalby. J Hypertens 10: 1071-8, 1992
44. Nilsson P, Andersson DKG, Andersson P-E, et al. Cardiovascular risk factors in treated hypertensives - a nation-wide, cross-sectional study in Sweden. J Internal Med 233: 239-45, 1993
45. Nilsson P, Lind L, Andersson P-E, Hänni A, Berne C, Baron J, Lithell H. On the use of ambulatory blood pressure recordings and insulin sensitivity in support of the insulin-hypertension hypothesis. J Hypertens 12: 965-9, 1994
46. Nilsson P, Möller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Internal Med 237: 479-86, 1995
47. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-93, 1994
48. Norris R, Valiquett T, Balagtas C. Comparison of troglitazone (CI991) dosing regimens and placebo in the treatment of patients with NIDDM. Diabetes 42 (suppl 1): abstract 187, 1993
49. Pershadsingh HA, Szollosi J, Benson J, Hyun WC, Fenerstein BG, Kurtz TW. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension 21: 1020-23, 1993
50. Pinkney JH, Nagi DK, Yudkin JS. From 'Syndrome X' to the thrifty phenotype: a reappraisal of the insulin resistance theory on atherogenesis. Vasc Med Rev 4: 19-47, 1993
51. Pinkney JH, Mohamed-Ali V, Denver E, Foster C, Sampson MJ, Yudkin JS. Insulin resistance, insulin, proinsulin, and ambulatory blood pressure in type II diabetes. Hypertension 24: 362-67, 1994
52. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorthiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868-73, 1989
53. Reaven GM. Role of insulin resistance in human disease. Diabetes 37: 1596-1607, 1988
54. Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 324: 733-9, 1991
55. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinnen V, Sarna S, Miettinen TA. Glucose tolerance and blood pressure: long term follow up in middle aged men. BMJ 302: 493-6, 1991
56. Simonsson DC. Etiology and prevalence of hypertension in diabetic patients. Diab Care 11: 821-7, 1988
57. Stern MP. Diabetes and cardiovascular disease. The "Common soil" hypothesis. Diab 44: 369-74, 1995
58. Sullivan M, Karlsson J, Sjöström L, et al. Swedish Obese Subjects (SOS) - an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1,743 subjects examined. Int J Obes 17: 503-12, 1993
59. Suter SL, Nolan JJ, Wallace P, Gumbiner N, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diab Care 15: 193-203, 1992
60. The CAPPP group. The Captopril Prevention Project: A prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertens 8: 985-90, 1990
61. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-86, 1993
62. The HOT Study Group. The Hypertension Optimal Treatment Study (The HOT Study). Blood Pressure 2: 62-8, 1993
63. The NORDIL Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood pressure 2: 312-21, 1993
64. The United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310: 83-8, 1995
65. Vague P, Juhan-Vague I, Alessi M, et al. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57: 326-8, 1987
66. Welin L, Eriksson H, Larsson B, et al. Hyperinsulinemia is not a major coronary risk factor in elderly men. The study of men born in 1913. Diabetologia 35: 766-70, 1992
67. Yoshioka S, Hishino H, Shiraki T, et al. Antihypertensive effect of CS-045 treatment in obese Zucker rats. Metabolism 42: 75-80, 1993
68. Yudkin JS. Circulating proinsulinlike molecules. J Diab Comp 7: 113-23, 1993